Spero Therapeutics (NASDAQ:SPRO) Given Buy Rating at HC Wainwright

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 481.46% from the stock’s current price.

SPRO has been the subject of several other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Finally, Evercore ISI lowered Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective on the stock. in a research report on Friday, December 20th.

Spero Therapeutics Trading Down 1.5 %

Shares of SPRO opened at $0.86 on Thursday. The company’s 50-day moving average price is $1.02 and its 200 day moving average price is $1.21. Spero Therapeutics has a 12-month low of $0.83 and a 12-month high of $1.89. The firm has a market cap of $46.88 million, a P/E ratio of 12.29 and a beta of 0.63.

Hedge Funds Weigh In On Spero Therapeutics

A hedge fund recently raised its stake in Spero Therapeutics stock. Renaissance Technologies LLC lifted its position in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 975,952 shares of the company’s stock after acquiring an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned 1.81% of Spero Therapeutics worth $1,269,000 at the end of the most recent quarter. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.